Bruker (NASDAQ:BRKR - Get Free Report) had its price target reduced by analysts at Barclays from $60.00 to $50.00 in a research report issued on Thursday,Benzinga reports. The brokerage presently has an "overweight" rating on the medical research company's stock. Barclays's price objective suggests a potential upside of 29.00% from the stock's previous close.
A number of other equities research analysts also recently weighed in on the stock. Guggenheim reaffirmed a "buy" rating on shares of Bruker in a research note on Monday, February 24th. Bank of America upped their target price on Bruker from $78.00 to $80.00 and gave the stock a "buy" rating in a research note on Friday, December 13th. Citigroup lowered their price objective on shares of Bruker from $75.00 to $50.00 and set a "buy" rating for the company in a report on Monday, April 7th. Finally, Stifel Nicolaus reduced their target price on shares of Bruker from $70.00 to $57.00 and set a "hold" rating on the stock in a report on Friday, February 14th. Six equities research analysts have rated the stock with a hold rating and six have given a buy rating to the company's stock. Based on data from MarketBeat, Bruker currently has a consensus rating of "Moderate Buy" and an average target price of $66.50.
View Our Latest Stock Analysis on BRKR
Bruker Stock Performance
Shares of Bruker stock traded up $0.69 during trading hours on Thursday, reaching $38.76. The company had a trading volume of 3,139,890 shares, compared to its average volume of 1,471,677. The company has a debt-to-equity ratio of 1.15, a current ratio of 1.60 and a quick ratio of 0.77. The firm has a market cap of $5.88 billion, a PE ratio of 51.00, a price-to-earnings-growth ratio of 2.16 and a beta of 1.18. Bruker has a one year low of $34.10 and a one year high of $88.51. The business has a fifty day simple moving average of $46.16 and a 200 day simple moving average of $54.64.
Bruker (NASDAQ:BRKR - Get Free Report) last released its quarterly earnings data on Thursday, February 13th. The medical research company reported $0.76 EPS for the quarter, beating analysts' consensus estimates of $0.75 by $0.01. Bruker had a net margin of 3.36% and a return on equity of 21.01%. On average, analysts anticipate that Bruker will post 2.69 earnings per share for the current fiscal year.
Institutional Trading of Bruker
Hedge funds and other institutional investors have recently modified their holdings of the business. Retirement Systems of Alabama increased its holdings in shares of Bruker by 11.7% during the third quarter. Retirement Systems of Alabama now owns 134,254 shares of the medical research company's stock valued at $9,272,000 after acquiring an additional 14,069 shares in the last quarter. Merit Financial Group LLC purchased a new position in Bruker in the 4th quarter worth approximately $300,000. Bank of New York Mellon Corp lifted its position in Bruker by 7.6% in the 4th quarter. Bank of New York Mellon Corp now owns 988,863 shares of the medical research company's stock valued at $57,967,000 after acquiring an additional 69,806 shares in the last quarter. Blue Trust Inc. boosted its position in shares of Bruker by 13.5% during the fourth quarter. Blue Trust Inc. now owns 2,164 shares of the medical research company's stock valued at $127,000 after buying an additional 257 shares during the last quarter. Finally, Allspring Global Investments Holdings LLC boosted its holdings in shares of Bruker by 1.8% during the 4th quarter. Allspring Global Investments Holdings LLC now owns 214,580 shares of the medical research company's stock valued at $12,619,000 after acquiring an additional 3,819 shares during the last quarter. 79.52% of the stock is owned by hedge funds and other institutional investors.
About Bruker
(
Get Free Report)
Bruker Corporation, together with its subsidiaries, develops, manufactures, and distributes scientific instruments, and analytical and diagnostic solutions in the United States, Europe, the Asia Pacific, and internationally. The company operates through four segments: Bruker Scientific Instruments (BSI) BioSpin, BSI CALID, BSI Nano, and Bruker Energy & Supercon Technologies.
Featured Articles
Before you consider Bruker, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Bruker wasn't on the list.
While Bruker currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
If a company's CEO, COO, and CFO were all selling shares of their stock, would you want to know? MarketBeat just compiled its list of the twelve stocks that corporate insiders are abandoning. Complete the form below to see which companies made the list.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
